Researchers have stopped testing a combination of remedesivir with one of Eli Lilly and Company’s experimental antibody treatments in hospitalized COVID-19 patients, after an independent review of results found a “lack of clinical benefit.”
The National Institute of Allergy and Infectious Diseases, which is funding the clinical trial, said in a statement Monday that it plans to test other experimental drugs as COVID-19 treatments in the study.
Eli Lilly and Company said that all other studies of its monoclonal antibody drug, bamlanivimab, will continue, including one in recently diagnosed COVID-19 patients with mild to moderate cases and another in people at risk of infection.
“While there was insufficient evidence that bamlanivimab improved clinical outcomes when added to other treatments in hospitalized patients with COVID-19, we remain confident based on data from Lilly’s BLAZE-1 study that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19,” Eli Lilly and Company said in a statement Monday.
Earlier this month, the Indianapolis-based pharmaceutical company asked the U.S. Food and Drug Administration to authorities emergency use of bamlanivimab in non-hospitalized individuals with mild to moderate cases of COVID-19.
